<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90212</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Emergent drugs (I): smart drugs</dc:title>
<dc:description xml:lang="en">In recent years, a series of new drugs, known assmart drugs or legal highs, have gaining in popularity.They are easily obtainable through online shops. Thisis happening amongst younger segments of the populationand is associated with recreational consumption,at weekends.In general, they are synthetic derivatives of naturalproducts. There has been hardly any clinical researchinto them and they are not detectable in hospital laboratories.Three of these products, BZP (1-benzylpiperazine),mefedrone (4-methylmethcathinone) and Spice are probablythe most widely used in Europe. The first two areconsumed as an alternative to ecstasy and cocaine andare characterized by their producing a clinical profile ofa sympathetic mimetic type; on occasion, they have seriousconsequences, with convulsions and even death.Spice (a mixture of herbs with synthetic cannabinoidssuch as JWH-018, JWH-073 and CP 47497-C8) is givingrise to profiles of dependence and schizophrenia.Although the emergent drugs have an aura of safety,there is an increasing amount of experience on theirsecondary effects(AU)</dc:description>
<dc:creator>Miró, Ó</dc:creator>
<dc:creator>Echarte, J. L</dc:creator>
<dc:creator>Puiguriguer, J</dc:creator>
<dc:creator>Climent, B</dc:creator>
<dc:creator>Munné, P</dc:creator>
<dc:creator>Burillo-Putze, G</dc:creator>
<dc:creator>Dargan, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En los últimos años han ganado popularidad unaserie de nuevas drogas, conocidas como smart drugs olegal highs, fácilmente accesibles a través de tiendas online.Ello ocurre sobre todo en los segmentos jóvenesde la población, asociado a su consumo lúdico fundamentalmentedurante los fines de semana.En general son derivados sintéticos de productosnaturales, de los que apenas existe investigación clínicay que no son detectables en los laboratorios de loshospitales.Tres de estos productos, el BZP (1-benzilpiperacina),la mefedrona (4-metilcatinona) y el Spice sonprobablemente los más utilizados en Europa. Los dosprimeros se consumen como alternativas al éxtasis y lacocaína, y se caracterizan por producir un cuadro clínicode tipo simpaticomimético, en ocasiones de consecuenciasgraves, con convulsiones e incluso muerte. ElSpice (mezcla de hierbas con cannabinoides sintéticoscomo el JWH-018, el JWH-073 y el CP 47,497-C8) estáocasionando cuadros de dependencia y esquizofrenia.Aunque las drogas emergentes poseen un aurade seguridad, cada vez hay más experiencia sobre susefectos secundarios(AU)</dc:description>
<dc:source>An Sist Sanit Navar;34(2): 263-274, mayo-ago. 2011. ilus</dc:source>
<dc:identifier>ibc-90212</dc:identifier>
<dc:title xml:lang="es">Drogas emergentes (I): las «smart drugs»</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33535^s22061</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33535^s22016</dc:subject>
<dc:subject>^d33535^s22024</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33535^s22053</dc:subject>
<dc:subject>^d33535^s22054</dc:subject>
<dc:subject>^d11312^s22020</dc:subject>
<dc:subject>^d11312^s22034</dc:subject>
<dc:subject>^d23605^s22020</dc:subject>
<dc:subject>^d11312^s22011</dc:subject>
<dc:subject>^d11312^s22055</dc:subject>
<dc:subject>^d23605^s22034</dc:subject>
<dc:subject>^d23605^s28898</dc:subject>
<dc:subject>^d23605^s22018</dc:subject>
<dc:type>article</dc:type>
<dc:date>201108</dc:date>
</metadata>
</record>
</ibecs-document>
